araag2/HINT huggingface dataset:
Clinical trial NCT00606021 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, best supportive care
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion criteria:

          1. You must be at least 18 years old

          2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)

          3. You must have had no prior systemic anticancer therapy for lung cancer

          4. You must live close enough to the study doctor to be able to visit regularly for
             follow up

          5. You must have signed informed consent form indicating your willingness to take part in
             this study

          6. Your laboratory and medical history and tests must meet study requirements

        Exclusion criteria:

          1. Treatment within the last 30 days with a drug that has not received regulatory
             approval for any indication at the time of study entry

          2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to
             initiation of treatment

          3. Serious concomitant systemic disorder (e.g., active infection including human
             immunodeficiency virus, or unstable cardiovascular disease)

          4. Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma
             skin cancer unless treated at least 5 years previously with no subsequent evidence of
             recurrence

          5. Brain metastasis

          6. Presence of clinically significant (by physical exam) third-space fluid collections,
             for example, ascites or pleural effusions that cannot be controlled by drainage or
             other procedures prior to study entry

          7. Significant weight loss (greater than 10%), over the previous 6 weeks before study
             entry

          8. Concurrent administration of any other antitumor therapy

          9. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a
             5-day period (8-day period for long-acting agents such as piroxicam)

         10. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or
             vitamin B12 supplementation

         11. Pregnancy or breast-feeding

         12. You are allergic to pemetrexed
Clinical trial NCT00337129 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: eribulin mesylate
SMILES: [H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and neck
             (SCCHN)

               -  Disease is either metastatic at diagnosis or has persisted, metastasized, or
                  recurred after definitive surgery and/or radiotherapy

               -  Not amenable to surgical resection for salvage therapy

               -  No newly diagnosed nonmetastatic disease

               -  No salivary or nasopharyngeal primary disease

               -  Patients who have failed primary surgery alone, and who have disease that is
                  salvageable by radiation or chemoradiation, are not eligible

          -  Measurable disease

               -  Measurable disease within a previous radiotherapy port must demonstrate clearly
                  progressive disease

          -  No active or prior CNS metastasis

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  Absolute granulocyte count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  SGOT and SGPT ≤ 2 times ULN

          -  Creatinine ≤ 2 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No known HIV positivity

          -  No prior malignancies except for the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  In situ cervical cancer

               -  Adequately treated stage I or II cancer currently in complete remission

               -  Any other cancer for which the patient has been disease free for ≥ 5 years

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy for recurrent or newly diagnosed metastatic disease

          -  At least 6 months since prior induction or adjuvant chemotherapy for patients who
             relapsed after receiving this therapy

               -  No more than 1 prior induction or adjuvant regimen (may have included a taxane)

          -  More than 2 weeks since prior biologic therapy (i.e., epidermal growth factor
             inhibitors and vascular endothelial growth factor inhibitors)

          -  More than 28 days since prior radiotherapy and recovered

          -  More than 28 days since prior surgery and recovered

          -  No other concurrent therapy (i.e., radiotherapy, chemotherapy, immunotherapy, biologic
             therapy, or gene therapy) for SCCHN

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent prophylactic colony-stimulating factors during course 1
Clinical trial NCT00568516 (phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: asp3550
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is a male patient with histologically proven prostate cancer (adenocarcinoma) of all
             stages

          -  Is a patient in whom endocrine treatment is indicated. Patients with rising serum PSA
             after having prostatectomy or radiotherapy performed with curative intention may be
             included

          -  Has a serum testosterone level above 1.5 ng/mL at screening

          -  Has an ECOG (Eastern Co-operative Oncology Group) P.S. (Performance Status) score of 0
             to 2

        Exclusion Criteria:

          -  Previous or present endocrine treatment for prostate cancer. However, patients who
             have undergone neoadjuvant/adjuvant endocrine therapy for a maximal duration of 6
             months and in whom prostatectomy or radiotherapy was terminated at least 6 months
             preceding Screening Visit may be included

          -  Is being treated with a 5α-reductase inhibitor

          -  Is a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy
             within 12 months

          -  Has concurrent or a history of severe asthma (defined as a need for daily treatment
             with inhalation steroids), anaphylactic reactions, severe urticaria and angioedema
Clinical trial NCT01061190 (phase 2/phase 3, status: completed)
Conditions: stroke
ICD codes: G46.4, G46.3, Z82.3
Drugs: propranolol
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Symptom onset within 18 hours

          -  Acute ischemic MCA-territory stroke

          -  Patients with suspected stroke in MCA-territory and a) NIHSS > 3 or b) imaging
             evidence of MCA-infarction

        Exclusion Criteria:

          -  Patients already receiving beta-blockers

          -  Anti-arrhythmic, antiinfectious, antiinflammatory or immunosuppressive therapy

          -  Patients with a major heart disease, hypotension, bradycardia or any contraindication
             to the use of Propranolol
Clinical trial NCT01145560 (phase 2, status: completed)
Conditions: severe sepsis, septic shock
ICD codes: R65.20, R65.21, T81.12XS, R65.20, R65.21, T81.12XA, T81.12XD
Drugs: azd9773, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with a first episode of sepsis during this hospitalisation and objective
             evidence of infection that requires parenteral antibiotics.

          -  At least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction (must include
             either fever OR elevated white blood cells [WBC])

          -  Cardiovascular or respiratory dysfunction.

        Exclusion Criteria:

          -  Immunocompromising comorbidities or concomitant medications:

               1. Advanced human immunodeficiency virus (HIV) infection (CD4 ≤50/mm3).

               2. Stage III or IV cancer.

               3. Haemopoietic or lymphoreticular malignancies not in remission.

               4. Receiving radiation therapy or chemotherapy.

               5. Stem cell, organ or bone marrow transplant in the past 6 months.

               6. Absolute neutrophil count <500 per μL.

               7. High dose steroids or other immunocompromising drugs.

          -  Concomitant diseases:

               1. Deep seated fungal infection or active tuberculosis.

               2. Cirrhosis with portal hypertension or Childs-Pugh Class C.

               3. History of chronic hypercarbia, respiratory failure in past 6 months or use of
                  home oxygen in the setting of severe chronic respiratory disease.

               4. Neuromuscular disorders that impact breathing/spontaneous ventilation.

               5. Quadriplegia.

               6. Cardiac arrest in the past 30 days.

               7. New York Heart Association functional Class IV due to heart failure or any
                  disorder.

               8. Burns over > 30% of body surface area.

          -  Medication and allergy disqualifications.

               1. Treatment with anti-TNF agents within the last 8 weeks.

               2. Previously received ovine derived products (CroFab™, DigiFab™).

               3. Sheep product allergy or allergy to latex, papain, chymopapain.
Clinical trial NCT00389792 (phase 2, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: ati-2042, ati-2042 200 mg
SMILES: CC[C@H](C)OC(=O)CC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2, CC[C@H](C)OC(=O)CC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Proven paroxysmal atrial fibrillation

          -  Pacemaker with appropriate AF diagnostics and recording capabilities

        Exclusion Criteria:

          -  Known allergy to Amiodarone or previous treatment for severe Amiodarone toxicity

          -  Cardioversion within one month of screening

          -  Severe left ventricular dysfunction or CHF with NYHA Class III or above
Clinical trial NCT02693210 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cyclophosphamide, methotrexate, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with moderate to severe rheumatoid arthritis (RA) who have previously
             failed 1-5 DMARDS who currently have partial clinical response to treatment with
             methotrexate

          -  Using methotrexate as a single DMARD for at least 16 weeks, of which the last 4 weeks
             prior to baseline on a stable oral dose greater than or equal to (>=) 10 milligrams
             per week (mg/week)

          -  >=21 years of age

          -  Swollen Joint Count (SJC) and Tender Joint Count (TJC) >= 8 (out of 66 and 68 joints
             respectively)

          -  At least 2 of the following parameters at Baseline: C- Reactive Protein >= 15 mg/dL;
             Erythrocyte Sedimentation Rate >= 30 millimeters per hour (mm/hr); Morning stiffness
             >45 minutes

          -  Rheumatoid factor titer >=20 International units per milliliter (IU/mL)

          -  Corticosteroid (less than or equal to [=<] 12.5 milligrams per deciliter [mg/d]
             prednisone or equivalent) or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are
             permitted if stable for at least 4 weeks prior to baseline

        Exclusion Criteria:

          -  American Rheumatism Association (ARA) Class IV RA disease

          -  Concurrent treatment with any DMARD (apart from randomized treatment) or
             anti-TNF-alpha therapy

          -  Active infection or history of recurrent significant infection

          -  Prior history of cancer including solid tumors and hematologic malignancies (except
             basal carcinoma of the skin that have been excised and cured)

          -  Evidence of serious uncontrolled concomitant diseases such as cardiovascular disease,
             nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders

          -  Bone/joint surgery within 6 weeks prior to screening

          -  Rheumatic Autoimmune disease other than RA

          -  Active rheumatoid vasculitis

          -  Prior history of gout

          -  Chronic fatigue syndrome
Clinical trial NCT00734474 (phase 2/phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, sitagliptin, placebo solution, placebo tablet, metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(O)=CC(C)=C1Cl, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diabetes mellitus, type 2, for at least 6 months

          -  Treatment regimens: diet and exercise, metformin as monotherapy or in combination with
             another oral antihyperglycemic medication (OAM), or another OAM as monotherapy. Must
             be able to tolerate metformin at a dose of at least 1500 milligrams (mg) daily for 6
             weeks prior to randomization.

          -  Glycosylated hemoglobin (HbA1c) value of ≥7.0% to ≤9.5%, except participants on diet
             and exercise therapy who must have had HbA1c value of >8.0% to ≤9.5%

          -  Body mass index (BMI) between 25 and 40 kilograms per meter squared (kg/m^2),
             inclusive

          -  Stable weight for 3 months prior to screening

          -  Females of childbearing potential must test negative for pregnancy and agree to use a
             reliable birth control method

        Exclusion Criteria:

          -  Diabetes mellitus, type 1

          -  Use of a glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6
             months prior to screening or are being treated with insulin

          -  Gastric emptying abnormality, history of bariatric surgery, or chronic use of drugs
             that affect gastrointestinal motility

          -  Use of medications to promote weight loss

          -  Clinically-relevant cardiovascular event within 6 months prior to screening

          -  Poorly controlled hypertension

          -  Electrocardiogram (ECG) reading considered outside the normal limits or indicating
             cardiac disease

          -  Liver disease, hepatitis, chronic pancreatitis, idiopathic acute pancreatitis, or
             alanine transaminase (ALT) levels >3.0 times the upper limit of normal

          -  Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) or a creatinine clearance <60
             milliliters per minute (mL/minute)

          -  Uncontrolled diabetes, defined as >2 episodes of ketoacidosis or hyperosmolar state
             requiring hospitalization in the 6 months prior to study entry.

          -  Uncontrolled endocrine or autoimmune abnormality

          -  History of a transplanted organ

          -  Chronic use of systemic glucocorticoid therapy

          -  Active or untreated malignancy

          -  Use of central nervous system (CNS) stimulants
Clinical trial NCT00623233 (phase 2, status: completed)
Conditions: metastatic breast cancer, locally advanced breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Must be female and greater than or equal to 18 yrs of age

          -  Participants must have confirmed cancer with measurable or evaluable, locally
             recurrent or metastatic disease.

          -  Participants must have received a taxane as neo-adjuvant and/or adjuvant therapy

          -  Participants may have received prior hormone therapy for locally recurrent or
             metastatic disease

        Exclusion Criteria:

          -  Participants with breast cancer overexpressing Human Epidermal growth factor Receptor
             2 (HER2) gene amplification

          -  Prior chemotherapy or targeted therapy for metastatic breast cancer

          -  Prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting

          -  History of, or active brain mets

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to treatment, or anticipation of need for major surgical procedure during course
             of study

          -  Prior history of high blood pressure crisis

          -  Have a serious, nonhealing wound, ulcer, or bone fracture
Clinical trial NCT01030965 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: gsk573719 125mcg, gsk573719 250mcg, gsk573719 500mcg, placebo
SMILES: OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A signed and dated written informed consent prior to study participation

          -  Males or females of non-childbearing potential

          -  40 to 80 years of age

          -  COPD diagnosis

          -  10 pack-years history or greater of cigarette smoking

          -  Post-bronchodilator FEV1/FVC ratio of 0.70 or less

          -  Post-bronchodilator FEV1 of 25 to 70% of predicted normal

        Exclusion Criteria:

          -  Asthma

          -  Other significant respiratory disorders besides COPD, including alpha-1 deficiency

          -  Previous lung resection surgery

          -  Chest X-ray or CP scan showing clinically significant abnormalities not due to COPD

          -  Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of
             screening

          -  Hospitalization for COPD or pneumonia within 3 months of screening

          -  Any significant disease that would put subject at risk through study participation

          -  BMI greater than 35

          -  Pacemaker

          -  Significantly abnormal ECG or clinical lab finding (including Hepatitis B or C)

          -  Cancer

          -  Allergy or hypersensitivity to anticholinergics or inhaler excipients

          -  Diseases that would contraindicate the use of anticholinergics

          -  Use of oral corticosteroids within 6 weeks of screening

          -  Use of long-acting beta-agonists within 48 hours of screening

          -  Use of tiotropium within 14 days of screening

          -  Use of theophyllines or anti-leukotrienes within 48 hours of screening

          -  Use of short-acting bronchodilators within 4 to 6 hours of screening

          -  Use of investigational medicines within 30 days of screening

          -  Use of high dose inhaled corticosteroids

          -  Use of long-term oxygen therapy, CPAP or NIPPV

          -  Participation in acute phase of pulmonary rehabilitation program

          -  History of alcohol or drug abuse within 2 years prior to screening

          -  History of psychiatric disease limiting validity of consent

          -  Affiliation with the investigative site

          -  Previous use of GSK573719
Clinical trial NCT01277341 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: bepotastine besilate nasal spray 2% twice a day, bepotastine besilate nasal spray 3% twice a day, bepotastine besilate nasal spray 4% twice a day, placebo nasal spray
SMILES: OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1, OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1, OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female at least 12 years of age with a history of mountain cedar allergy

        Exclusion Criteria:

          -  No active nasal infection or nasal abnormality that would affect subject safety or
             symptom assessments
Clinical trial NCT00492284 (phase 2, status: completed)
Conditions: choroidal neovascularization, macular degeneration
ICD codes: H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211, H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: verteporfin, verteporfin, ranibizumab, dexamethasone
SMILES: COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment naive for choroidal neovascularization (CNV) secondary to age-related
             macular degeneration (AMD) in the study eye except for laser treatment outside the
             subfoveal area

          -  Subfoveal CNV due to AMD

          -  CNV must be = or >50 % of the entire lesion

          -  All lesion composition types with a lesion greatest linear dimension (GLD) < 5400
             microns (approximately = or <9 disc areas [DA])

          -  Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA
             score) of 25 - 73 letters (approximate Snellen equivalent of 20/40 - 20/320),
             inclusive

        Exclusion Criteria:

          -  Subfoveal geographic atrophy or subfoveal fibrosis of the study eye

          -  Intraocular surgery within 3 months of enrollment

          -  Inability to attend the protocol-required visits

          -  Known allergies or hypersensitivity to any of the study treatments.

          -  Other systemic diseases or active uncontrolled infections that would make subject a
             poor medical risk

          -  Uncontrolled glaucoma, defined as (1)subject is on >1 glaucoma medication (includes
             combination treatments) or (2)subject has glaucoma that could lead to progressive
             visual field deterioration

          -  If subject has had a stroke within the last year